Piekos Brian sold 1,489 shares of KalVista Pharmaceuticals, Inc. at $26.78 for −$39.9k on May 22, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Chief Financial Officer
Chief Financial Officer
Filed May 26, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$39,881.97Shares × reported price
Shares traded
1,489Common Stock
Price per share
$26.78Reported price. Read footnotes for ranges.
% of reported position traded
6.43%This security and ownership context
Holdings after
21,661Direct
Trade date
May 22, 2026Sell
Filed
May 26, 2026, 7:32 PM ET4-day reporting delay
Accession
0001815308-26-000004Code S · Transaction 385424
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 23,150 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
May 21, 2026Option exercise5,000$0.00$0Trade 385425
May 21, 2026Option exercise5,000——Trade 385423
3 transaction rows in this filing. Joint filers share the same rows.

KALV price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
KALV · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −27%1w ago −0.3%1d ago −0.1%
Returns since7d +0.5%30d +0.7%90d +0.7%180d1y

Footnotes in full

F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3: 3/16th of the total number of shares underlying the RSUs vested on November 21, 2025 and 1/16 shall vest on each quarterly anniversary of the Vesting Commencement Date thereafter, for so long as grantee's Service (as defined in the Plan) does not terminate.